Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 4, 1996, Pages 411-417

  Hou, Zone Yuan ^a   Chen, Ching Pu ^b   Yang, Wu Chang ^b   Lai, Ming Derg ^b   Buchert, Elaine T ^b   Chung, Hsiao Min ^b   Pickle, Linda W ^b   Woosley, Raymond L ^b  

^a God's Help Hospital   (Taiwan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; DEXTROMETHORPHAN; DRUG METABOLITE; QUINIDINE SULFATE;

ADULT; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SALIVA ANALYSIS;

ADULT; ANTI-ARRHYTHMIA AGENTS; CHINA; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; FEMALE; GENOTYPE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHENOTYPE; QUINIDINE; RENAL DIALYSIS; SALIVA; TAIWAN;

EID: 0029923510     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90109-5     Document Type: Article

References (27)

1. Gonzalez FJ, Skoda RC, Kimura S, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988;331: 442-6.
2. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol Ther 1990;46:377-94.
3. Wang T, Roden DM, Wolfenden HT, Woosley RL, Wood AJ, Wilkinson GR. Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J Pharmacol Exp Ther 1984;228:605-11.
4. Woosley RL, Roden DM, Dai G, et al. Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. CLIN PHARMACOL THER 1986;39:282-7.
5. Siddoway LA, Thompson KA, McAllister B, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987;75:785-91.
6. Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism: cosegregation of oxidative O-demethylation with debrisoquin hydroxylation. CLIN PHARMACOL THER 1985;38:618-24.
7. Henthorn TK, Benitez J, Avram MJ, et al. Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis. CLIN PHARMACOL THER 1989;45:328-33.
8. Larrey D, Babany G, Tinel M, et al. Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients. Br J Clin Pharmacol 1989;28:297-304.
9. Hou ZY, Pickle LM, Meyer PS, Woosley RL. Salivary analysis for determination of dextromethorphan metabolic phenotype. CLIN PHARMACOL THER 1991;49:410-9.
10. Otton SV, Inaba T, Kalow W. Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 1983;34:73-80.
11. Speirs CJ, Murray S, Boobis AR, Seddon CE, Davies DS. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br J Clin Pharmacol 1986;22:739-43.
12. Inaba T, Tyndale RE, Mahon WA. Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo [Letter]. Br J Clin Pharmacol 1986;22:199-200.
13. Brinn R, Brøsen K, Gram LF, Haghfelt T, Otton SV. Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol 1986; 22:194-7.
14. Zhang Y, Britto MR, Valderhaug KL, Wedlund PJ, Smith RA. Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. CLIN PHARMACOL THER 1992;51:647-55.
15. Buchert ET, Woosley RL, Swain SM, et al. Relationship of CYP2D6 (debrisoquine hydroxylase) genotype to breast cancer susceptibility. Pharmacogenetics 1993;3:322-7.
16. Walsh SP, Metzger DA, Higuchi R. Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. Biotechniques 1991;10: 506-13.
17. 1934→A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am J Hum Genet 1990;47:994-1001.
18. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. CLIN PHARMACOL THER 1993;53:410-8.
19. Lou YC, Ying L, Bertilsson L, Sjoqvist F. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 1987;2:852-3.
20. Horai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. CLIN PHARMACOL THER 1989;46:198-207.
21. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P450db1 gene (P450IID1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 1988;85:5240-3.
22. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336;529-32.
23. Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjoqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. CLIN PHARMACOL THER 1992;51:12-7.
24. Yue QY, Bertilsson L, Dahl-Puustinen ML, et al. Dissociation between debrisoquine hydroxylation phenotype and genotype among Chinese [Letter]. Lancet 1989;2:870.
25. Mura C, Broyard JP, Jacqz-Aigrain E, Krishnamoorthy R. Distinct phenotypes and genotypes of debrisoquine hydroxylation among Europeans and Chinese [Letter]. Br J Clin Pharmacol 1991;32:135-6.
26. Mikus G, Gross AS, Beckmann J, Hertrampf R, Gundert-Remy U, Eichelbaum M. The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. CLIN PHARMACOL THER 1989;45: 562-7.
27. Turgeon J, Evans WE, Relling MV, Wilkinson GR, Roden DM. Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba I restriction fragment length polymorphism. Br J Clin Pharmacol 1991;32:283-8.